Personalized 'Living Drug' trial targets Tough-to-Treat kidney cancer
NCT ID NCT06245915
Summary
This study is testing a new cell therapy called AB-2100 for people with advanced kidney cancer that has come back or spread after standard treatments. Doctors take a patient's own immune cells, genetically modify them to better recognize and attack cancer, and infuse them back into the body. The main goals are to find a safe dose and see if this approach can shrink tumors in patients who have run out of other options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENCE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Dana Farber Cancer Institue
Boston, Massachusetts, 02215, United States
-
Huntsman Cancer Institute - Univ of Utah Health
Salt Lake City, Utah, 84112, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic Hospital
Phoenix, Arizona, 85054, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Perlmutter Cancer Center - NYU Langone Health
New York, New York, 10016, United States
-
University of Iowa and Holden Comprehensive Cancer Center
Iowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.